病院感染治療薬市場：薬剤タイプ別、感染症別-2025-2030年の世界予測

病院感染治療薬市場の2023年の市場規模は59億米ドルで、2024年には63億8,000万米ドルに達すると予測され、CAGR 8.27％で成長し、2030年には102億9,000万米ドルに達すると予測されています。

病院感染治療薬市場は、病院環境で発症する感染症の治療と管理に焦点を当てたヘルスケア産業の専門分野です。これらの感染症はしばしば院内感染またはヘルスケア関連感染（HAI）と呼ばれ、MRSA、C. difficile、血流感染などの疾患が含まれます。HAIは入院期間の延長、医療費の増加、死亡率の上昇につながるため、このような治療薬の必要性が高まっています。病院感染治療薬の用途は抗生物質、抗ウイルス剤、抗真菌剤に及び、主に感染症を専門とする臨床医が病院環境で使用しています。最終用途には、病院、診療所、感染症専門治療センターなどが含まれます。この市場に影響を与える主な成長要因としては、高齢者人口の増加、外科手術の増加、早期発見につながる診断ツールの進歩などが挙げられます。さらに、感染予防と制御を目的とした政府の取り組みが、市場拡大の可能性を生み出しています。最近のバイオテクノロジーの革新と創薬におけるAIの登場は、有望な機会を提示しています。しかし、市場の成長は、抗生物質耐性や厳しい規制当局の承認などの課題に直面しており、製品の発売や技術革新を遅らせる可能性があります。この市場における技術革新は、新しい抗菌剤、ファージ療法のような代替療法、治療効果を高める迅速診断テストの開発に集中すると思われます。製薬企業と研究機関の戦略的提携は、高い研究開発費などの制約を克服するのに役立ちます。研究開発、特に患者固有の感染プロファイルに合わせた個別化医療アプローチへの投資を通じて、事業の成長は可能です。さらに、ビッグデータ解析を活用することで、感染パターンに関する洞察を提供し、治療介入を最適化することができます。同市場は競合情勢にあり、治療薬に対する継続的なニーズが原動力となっているため、新たな感染課題や規制状況に対応するための機敏なイノベーションが必要とされています。

市場力学：急速に進化する病院感染治療薬市場の主要市場インサイトを公開

病院感染治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の増加に伴う老人人口の増加
  • 感染管理政策の急速な重視
  • 償還政策の改善
• 市場抑制要因
  • 製品リコールに関する懸念
• 市場機会
  • 病院感染治療薬に関する研究開発投資の増加
  • 政府による好意的な医薬品・投薬の承認
• 市場の課題
  • 院内感染に関する厳しい規制要件

ポーターの5つの力：病院感染治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：病院感染治療薬市場における外部からの影響の把握

外部マクロ環境要因は、病院感染治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析病院感染治療薬市場における競合情勢の把握

病院感染治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス病院感染治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、病院感染治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨病院感染治療薬市場における成功への道筋を描く

病院感染治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品上市、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加に伴う高齢者人口の増加
    • 感染対策政策への重点が急速に高まっている
    • 払い戻しポリシーの改善
  • 抑制要因
    • 製品リコールに関する懸念
  • 機会
    • 病院感染治療薬の研究開発への投資増加
    • 政府による医薬品の承認
  • 課題
    • 院内感染に対する厳格な規制要件
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 病院感染治療薬市場薬の種類別

• 抗菌薬
• 抗真菌薬
• 抗ウイルス薬

第7章 病院感染治療薬市場感染症別

• 血流感染症
• 胃腸障害
• 院内肺炎
• 手術部位感染
• 尿路感染症

第8章 南北アメリカの病院感染治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の病院感染治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの病院感染治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• AstraZeneca PLC
• Basilea Pharmaceutica Ltd.
• Bayer AG
• Bristol Myers Squibb Company
• Daiichi Sankyo Company, Limited
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi S.A.
• Spero Therapeutics

LIST OF FIGURES

• FIGURE 1. HOSPITAL INFECTION THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HOSPITAL INFECTION THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HOSPITAL INFECTION THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBACTERIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL-ACQUIRED PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SURGICAL SITE INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 24. CANADA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 25. CANADA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 36. CHINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CHINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 38. INDIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. INDIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 73. ITALY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ITALY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 81. POLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 82. POLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 83. QATAR HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. QATAR HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 103. HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 104. HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Hospital Infection Therapeutics Market was valued at USD 5.90 billion in 2023, expected to reach USD 6.38 billion in 2024, and is projected to grow at a CAGR of 8.27%, to USD 10.29 billion by 2030.

The Hospital Infection Therapeutics market is a specialized segment of the healthcare industry focused on the treatment and management of infections acquired in hospital settings. These infections, often termed nosocomial or healthcare-associated infections (HAIs), include conditions such as MRSA, C. difficile, and bloodstream infections. The necessity for such therapeutics has risen due to the increasing incidence of HAIs, which contribute to prolonged hospital stays, higher healthcare costs, and significant mortality rates. The application of hospital infection therapeutics spans antibiotics, antiviral, and antifungal agents, used primarily in hospital environments by clinicians specializing in infectious diseases. End-use sectors include hospitals, clinics, and specialized infection treatment centers. Key growth factors influencing this market include the growing geriatric population, increasing surgical procedures, and advancements in diagnostic tools leading to early detection. Moreover, government initiatives aimed at infection prevention and control create potential for market expansion. Recent biotechnology innovations and the advent of AI in drug discovery present promising opportunities. However, market growth faces challenges such as antibiotic resistance and stringent regulatory approvals, which can delay product launches and innovation. Innovations in this market are likely to focus on developing new antimicrobial agents, alternative therapies like phage therapy, and rapid diagnostic tests that enhance treatment efficacy. Strategic collaborations among pharmaceutical companies and research institutions can help overcome limitations such as high R&D costs. Business growth is feasible through investments in R&D, especially in personalized medicine approaches tailored to patient-specific infection profiles. Additionally, leveraging big data analytics can provide insights into infection patterns, optimizing therapeutic interventions. The market is competitive, driven by continuous need for improved therapeutics, and necessitates agile innovation to address emerging infection challenges and regulatory landscapes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hospital Infection Therapeutics Market

The Hospital Infection Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing geriatric population with the increase in the number of chronic diseases
  • Rapidly growing emphasis on infection control policies
  • Improvements in reimbursement policies
• Market Restraints
  • Concerns related to product recalls
• Market Opportunities
  • Increasing investments in R&D on hospital infection therapeutics
  • Favorable drug and medication approvals by government
• Market Challenges
  • Stringent Regulatory Requirements for Hospital Acquired Infection

Porter's Five Forces: A Strategic Tool for Navigating the Hospital Infection Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hospital Infection Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hospital Infection Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hospital Infection Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hospital Infection Therapeutics Market

A detailed market share analysis in the Hospital Infection Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hospital Infection Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hospital Infection Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hospital Infection Therapeutics Market

A strategic analysis of the Hospital Infection Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hospital Infection Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., and Spero Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Hospital Infection Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Antibacterial Drugs, Antifungal Drugs, and Antiviral Drugs.
• Based on Infections, market is studied across Bloodstream Infections, Gastrointestinal Disorders, Hospital-Acquired Pneumonia, Surgical Site Infections, and Urinary Tract Infection.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing geriatric population with the increase in the number of chronic diseases
    • 5.1.1.2. Rapidly growing emphasis on infection control policies
    • 5.1.1.3. Improvements in reimbursement policies
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns related to product recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investments in R&D on hospital infection therapeutics
    • 5.1.3.2. Favorable drug and medication approvals by government
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent Regulatory Requirements for Hospital Acquired Infection
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hospital Infection Therapeutics Market, by Drug Type

• 6.1. Introduction
• 6.2. Antibacterial Drugs
• 6.3. Antifungal Drugs
• 6.4. Antiviral Drugs

7. Hospital Infection Therapeutics Market, by Infections

• 7.1. Introduction
• 7.2. Bloodstream Infections
• 7.3. Gastrointestinal Disorders
• 7.4. Hospital-Acquired Pneumonia
• 7.5. Surgical Site Infections
• 7.6. Urinary Tract Infection

8. Americas Hospital Infection Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Hospital Infection Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Hospital Infection Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. AstraZeneca PLC
• 4. Basilea Pharmaceutica Ltd.
• 5. Bayer AG
• 6. Bristol Myers Squibb Company
• 7. Daiichi Sankyo Company, Limited
• 8. F. Hoffmann-La Roche Ltd.
• 9. Gilead Sciences Inc.
• 10. GlaxoSmithKline PLC
• 11. Johnson & Johnson Services Inc.
• 12. Merck & Co., Inc.
• 13. Pfizer Inc.
• 14. Sanofi S.A.
• 15. Spero Therapeutics